ArticleNucleic acids research2025
Targeted translation inhibition of chloroplast and mitochondrial mRNAs by designer pentatricopeptide repeat proteins.
Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pentatricopeptide repeat proteins in crops: Advances in functional mechanisms and breeding applications.Journal of integrative plant biology · 2026Review
- Synthetic Pentatricopeptide Repeat Proteins: Building a Toolkit for Precise RNA Control.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pentatricopeptide repeat (PPR) proteins are crucial for organellar gene expression. To establish a tool for gene expression manipulation in Arabidopsis plastids and genetically inaccessible mitochondria, we engineered designer (dPPR) proteins to specifically inhibit the translation of organellar mRNAs by masking their start codons. Unlike prior methods for targeted downregulation of gene expression, which rely on re-targeting native PPR proteins to RNA sequences closely related to their original targets, our approach employs a synthetic P-type PPR scaffold that can be designed to bind any RNA sequence of interest. Here, using dPPR-psbK and dPPR-nad7, we targeted the psbK mRNA in chloroplasts and the nad7 mRNA in mitochondria, respectively. dPPR-psbK effectively bound to psbK mRNA and inhibited its translation with high specificity, resulting in disrupted PSII supercomplexes and reduced photosynthetic efficiency. dPPR-nad7 suppressed nad7 translation, affecting NADH oxidase activity in complex I and growth retardation. Comparing phenotypes with tobacco psbK knockouts and nad7 knockdown bir6-2 mutants, along with quantitative proteomics, showed no clear evidence of physiologically relevant off-target effects. Our findings establish dPPR proteins as precise tools for targeted translation inhibition, facilitating functional studies of organellar genes and offering a novel approach with potential for manipulating organellar gene expression in diverse plant species.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.